compounded semaglutide no longer available Hims no longer prescribes glp1s

A Phase 2 study published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported substantial weight loss in participants with obesity

Tirzepatide is technically a dual GIP and GLP-1 receptor agonist, but many patients group it with GLP-1 weight-loss injections because it affects the GLP-1 pathway

Like many people struggling with weight loss, I wanted something that seemed newer and more effective than traditional medications

Even when its wanted

This dual mechanism produces even stronger appetite suppression and weight loss results in clinical trials

Learning to spot the hidden fillers on supplement labels, and choosing clean capsule materials like pullulan capsules, which are fermented and add a small prebiotic benefit of their own, means the bacteria you're introducing aren't fighting the very additives meant to deliver them